Recognizing and Supporting Leaders and Visionaries in Pain
Each year, APS rewards excellence in the field of pain management, and promotes pain research by presenting awards and grants to people making a difference in pain medicine. Awards are given for career achievement, pain scholarship, education, public services, advocacy, and outstanding service to APS. Grants are awarded to investigators in different branches of pain research, whose projects will lead to new methods of pain management and add to the existing body of knowledge. Follow the links below for more information on specific awards and grants, and about past recipients and how to apply.
Congratulations to the 2018 APS Award Winners!
|Distinguished Service Award
Christopher M. Herndon, PharmD CPE
|Elizabeth Narcessian Award
Rollin M. Gallagher, MD MPH
|Frederick W.L. Kerr Basic
Science Research Award
Robert C. Coghill, PhD
|Jeffrey Lawson Award for
Advocacy in Children's Pain Relief
Ruth E. Grunau, PhD
|John and Emma Bonica
Public Service Award
Lorimer Moseley, DSc PhD
|John C. Liebeskind
Early Career Scholar Award
Jessica S. Merlin, MD PhD
|Wilbert E. Fordyce
Clinical Investigator Award
Beverly E. Thorn, PhD
Clinical Centers of Excellence*
The Clinical Centers of Excellence in Pain Management Award Program honors U.S.-based multidisciplinary healthcare teams who provide the most distinguished, comprehensive pain care. Any qualifying clinical program that provides direct patient care focused on pain treatment is encouraged to apply.
*CCOE is on hiatus while our experts redesign the program so that we may continue to recognize the best interdisciplinary care in the field.
The Rita Allen Foundation and APS Award in Pain Grant is awarded to two pain research proposals focused on the molecular biology of pain or basic science topics related to the development of new analgesics for the management of pain due to terminal illness.
The APS Future Leaders in Pain Research grants program funds the research projects of young investigators who have not yet attained NIH RO1 level funding.